vvDD-hIL-2-RG-1
Phase 1Biologic
vvDD-hIL-2-RG-1 is one of 7 biologic programs targeting Gastrointestinal. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gastrointestinal
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Phase 3
Cytalux
OOn Target Laboratories, LLC
Phase 3
Octreotide
Johnson & JohnsonPreclinical
vvDD-hIL-2-RG-1
AAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1
Mosapride Citrate
IlDong Pharmaceutical Co LtdPreclinical
Buscopan
Boehringer IngelheimPreclinical
Dachengqi Decoction
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastrointestinal1 trial
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Recruiting·—·Phase 1·NCT07001592·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vvDD-hIL-2-RG-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details